<DOC>
	<DOCNO>NCT01505088</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy ocular iontophoresis dexamethasone phosphate ophthalmic solution EGP-437 use EyeGate® II Drug Delivery System ( EGDS ) compare prednisolone acetate ophthalmic suspension ( 1 % ) patient non-infectious anterior segment uveitis .</brief_summary>
	<brief_title>Safety Efficacy Study Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Treat Non-Infectious Anterior Segment Uveitis</brief_title>
	<detailed_description>Anterior uveitis disorder eye associate intraocular inflammation anterior portion uvea , particularly iris and/or ciliary body . It distinct iteration uveitis posterior , diffuse intermediate uveitis although common form uveitis account approximately 75 % case . In Phase 1/2 study ( EGP-437-001 ) , delivery EGP-437 ( 40 mg/mL dexamethasone phosphate solution ) four different iontophoresis dose level study 40 subject non-infectious anterior segment uveitis . The study demonstrate single EGP-437 treatment : lower anterior chamber cell ( ACC ) score majority patient without require additional treatment ; produce low short-term systemic exposure dexamethasone dexamethasone phosphate ; produce beneficial effect 1.6 4.8 mA-min dose group ; cause mainly minor AEs non-ocular systemic corticosteroid mediate effect observe . The Phase 3 study intend confirm extend result Phase 2 study . The study design assess safety efficacy Ocular Iontophoresis EGP-437 4.0 mA-min 1.5 mA accompany placebo eyedrop comparison Ocular Iontophoresis sodium citrate buffer solution 4.0 mA-min 1.5 mA accompany prednisolone acetate ( 1 % ) eyedrops treatment non-infectious anterior segment uveitis .</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Uveitis , Anterior</mesh_term>
	<mesh_term>Iridocyclitis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<mesh_term>Benzalkonium Compounds</mesh_term>
	<criteria>Male female , age 12 85 year diagnosis noninfectious anterior segment uveitis define anterior chamber cell count ≥ 11 cell Receive , understand , sign copy write informed consent form Be able return study visit willing comply studyrelated instruction Have uveitis infectious etiology Have active intermediate posterior uveitis Known positive HLAB27 severe ( 4+ ) fibrinoid reaction Have previous anterior segment uveitis episode study eye ≤ 4 week prior baseline visit Have use topical corticosteroid treatment study eye ≤ 48 hour prior baseline visit Have use oral corticosteroid within past 14 day prior baseline Have receive intravitreal subTenon corticosteroid treatment study eye within past 6 month prior baseline visit Currently use prescribe nonsteroidal antiinflammatory agent ( i.e. , use overthecounter dosage allowable ) prescribe immunosuppressive agent , unless dose stable last six week change dose anticipate duration study Have IOP ≥ 25 mmHg baseline , history glaucoma , require ocular antihypertensive medication study eye Be know steroid intraocular pressure responder either eye Have open wounds/skin disease forehead area iontophoresis return electrode apply Have severe lesion eyelid ocular surface impede application iontophoresis applicator Have know allergy dexamethasone dexamethasone phosphate medication use study Have history diagnosis ocular herpes , corneal lesion suspect herpetic origin , Behçet 's disease Have monocular BCVA worse 20/80 fellow eye Have optic neuritis origin Have clinically suspect confirmed central nervous system ocular lymphoma Planning undergo elective ocular surgery study Have active hyphema , par planitis , choroiditis , clinically significant macular edema , toxoplasmosis scar , vitreous hemorrhage Have severe/serious ocular pathology medical condition may preclude study completion Have pacemaker and/or electrical sensitive support system Be pregnant lactate female , female childbearing age use inadequate birth control method Have participate another investigational device drug study within 30 day baseline visit Have significant Fuch 's Corneal Dystrophy</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Iontophoresis</keyword>
	<keyword>Non-Infectious Anterior Segment Uveitis</keyword>
	<keyword>Ophthalmology</keyword>
</DOC>